163 related articles for article (PubMed ID: 38281068)
1. Vutrisiran: a new drug in the treatment landscape of hereditary transthyretin amyloid polyneuropathy.
Planté-Bordeneuve V; Perrain V
Expert Opin Drug Discov; 2024 Apr; 19(4):393-402. PubMed ID: 38281068
[TBL] [Abstract][Full Text] [Related]
2. Vutrisiran: A Review in Polyneuropathy of Hereditary Transthyretin-Mediated Amyloidosis.
Nie T; Heo YA; Shirley M
Drugs; 2023 Oct; 83(15):1425-1432. PubMed ID: 37728865
[TBL] [Abstract][Full Text] [Related]
3. Indirect treatment comparison (ITC) of the efficacy of vutrisiran and tafamidis for hereditary transthyretin-mediated amyloidosis with polyneuropathy.
Merkel M; Danese D; Chen C; Wang J; Wu A; Yang H; Lin H
Expert Opin Pharmacother; 2023; 24(10):1205-1214. PubMed ID: 37219406
[TBL] [Abstract][Full Text] [Related]
4. Efficacy and safety of vutrisiran for patients with hereditary transthyretin-mediated amyloidosis with polyneuropathy: a randomized clinical trial.
Adams D; Tournev IL; Taylor MS; Coelho T; Planté-Bordeneuve V; Berk JL; González-Duarte A; Gillmore JD; Low SC; Sekijima Y; Obici L; Chen C; Badri P; Arum SM; Vest J; Polydefkis M;
Amyloid; 2023 Mar; 30(1):1-9. PubMed ID: 35875890
[TBL] [Abstract][Full Text] [Related]
5. Impact of Vutrisiran on Quality of Life and Physical Function in Patients with Hereditary Transthyretin-Mediated Amyloidosis with Polyneuropathy.
Obici L; Ajroud-Driss S; Lin KP; Berk JL; Gillmore JD; Kale P; Koike H; Danese D; Aldinc E; Chen C; Vest J; Adams D;
Neurol Ther; 2023 Oct; 12(5):1759-1775. PubMed ID: 37523143
[TBL] [Abstract][Full Text] [Related]
6. Characteristics of Patients with Hereditary Transthyretin Amyloidosis-Polyneuropathy (ATTRv-PN) in NEURO-TTRansform, an Open-label Phase 3 Study of Eplontersen.
Coelho T; Waddington Cruz M; Chao CC; Parman Y; Wixner J; Weiler M; Barroso FA; Dasgupta NR; Jung SW; Schneider E; Viney NJ; Dyck PJB; Ando Y; Gillmore JD; Khella S; Gertz MA; Obici L; Berk JL
Neurol Ther; 2023 Feb; 12(1):267-287. PubMed ID: 36525140
[TBL] [Abstract][Full Text] [Related]
7. A mini-review of Vutrisiran and Eplontersen in hereditary transthyretin-mediated amyloidosis with polyneuropathy.
Olatunji G; Kokori E; Abraham IC; Omoworare O; Olatunji D; Ezeano C; Emmanuel Adeoba B; Stanley AC; Oluwatobiloba AM; Oluwademilade OB; Shimelis KM; Olanisa O; Aderinto N
Medicine (Baltimore); 2024 Jun; 103(26):e38767. PubMed ID: 38941378
[TBL] [Abstract][Full Text] [Related]
8. Impact of Baseline Neuropathy Severity on Vutrisiran Treatment Response in the Phase 3 HELIOS-A Study.
Luigetti M; Quan D; Berk JL; Conceição I; Misumi Y; Chao CC; Bender S; Aldinc E; Vest J; Adams D
Neurol Ther; 2024 Jun; 13(3):625-639. PubMed ID: 38512694
[TBL] [Abstract][Full Text] [Related]
9. Impact of vutrisiran on exploratory cardiac parameters in hereditary transthyretin-mediated amyloidosis with polyneuropathy.
Garcia-Pavia P; Grogan M; Kale P; Berk JL; Maurer MS; Conceição I; Di Carli M; Solomon SD; Chen C; Yureneva E; Vest J; Gillmore JD
Eur J Heart Fail; 2024 Feb; 26(2):397-410. PubMed ID: 38321786
[TBL] [Abstract][Full Text] [Related]
10. Vutrisiran: First Approval.
Keam SJ
Drugs; 2022 Sep; 82(13):1419-1425. PubMed ID: 35997942
[TBL] [Abstract][Full Text] [Related]
11. Disease-Modifying Drugs Extend Survival in Hereditary Transthyretin Amyloid Polyneuropathy.
Ueda M; Misumi Y; Nomura T; Tasaki M; Yamakawa S; Obayashi K; Yamashita T; Ando Y
Ann Neurol; 2024 Feb; 95(2):230-236. PubMed ID: 38053464
[TBL] [Abstract][Full Text] [Related]
12. Novel approaches to diagnosis and management of hereditary transthyretin amyloidosis.
Carroll A; Dyck PJ; de Carvalho M; Kennerson M; Reilly MM; Kiernan MC; Vucic S
J Neurol Neurosurg Psychiatry; 2022 Jun; 93(6):668-678. PubMed ID: 35256455
[TBL] [Abstract][Full Text] [Related]
13. Inotersen for the treatment of adults with polyneuropathy caused by hereditary transthyretin-mediated amyloidosis.
Gertz MA; Scheinberg M; Waddington-Cruz M; Heitner SB; Karam C; Drachman B; Khella S; Whelan C; Obici L
Expert Rev Clin Pharmacol; 2019 Aug; 12(8):701-711. PubMed ID: 31268366
[No Abstract] [Full Text] [Related]
14. Red flags and adjusted suspicion index for distinguishing hereditary transthyretin amyloid polyneuropathy from idiopathic axonal polyneuropathy.
Warendorf JK; van der Star GM; Dooijes D; Notermans NC; Vrancken AFJE
Neurol Sci; 2023 Oct; 44(10):3679-3685. PubMed ID: 37266816
[TBL] [Abstract][Full Text] [Related]
15. Design and Rationale of the Global Phase 3 NEURO-TTRansform Study of Antisense Oligonucleotide AKCEA-TTR-L
Coelho T; Ando Y; Benson MD; Berk JL; Waddington-Cruz M; Dyck PJ; Gillmore JD; Khella SL; Litchy WJ; Obici L; Monteiro C; Tai LJ; Viney NJ; Buchele G; Brambatti M; Jung SW; St L O'Dea L; Tsimikas S; Schneider E; Geary RS; Monia BP; Gertz M
Neurol Ther; 2021 Jun; 10(1):375-389. PubMed ID: 33638113
[TBL] [Abstract][Full Text] [Related]
16. Diagnosis and treatment of hereditary transthyretin amyloidosis with polyneuropathy in the United States: Recommendations from a panel of experts.
Karam C; Mauermann ML; Gonzalez-Duarte A; Kaku MC; Ajroud-Driss S; Brannagan TH; Polydefkis M
Muscle Nerve; 2024 Mar; 69(3):273-287. PubMed ID: 38174864
[TBL] [Abstract][Full Text] [Related]
17. Long-term efficacy and safety of inotersen for hereditary transthyretin amyloidosis: NEURO-TTR open-label extension 3-year update.
Brannagan TH; Coelho T; Wang AK; Polydefkis MJ; Dyck PJ; Berk JL; Drachman B; Gorevic P; Whelan C; Conceição I; Plante-Bordeneuve V; Merlini G; Obici L; Plana JMC; Gamez J; Kristen AV; Mazzeo A; Gentile L; Narayana A; Olugemo K; Aquino P; Benson MD; Gertz M;
J Neurol; 2022 Dec; 269(12):6416-6427. PubMed ID: 35908242
[TBL] [Abstract][Full Text] [Related]
18. Real-world outcomes in non-endemic hereditary transthyretin amyloidosis with polyneuropathy: a 20-year German single-referral centre experience.
Ungerer MN; Hund E; Purrucker JC; Huber L; Kimmich C; Aus dem Siepen F; Hein S; Kristen AV; Hinderhofer K; Kollmer J; Schönland S; Hegenbart U; Weiler M
Amyloid; 2021 Jun; 28(2):91-99. PubMed ID: 33283548
[TBL] [Abstract][Full Text] [Related]
19. Corneal confocal microscopy identifies corneal nerve loss and increased Langerhans cells in presymptomatic carriers and patients with hereditary transthyretin amyloidosis.
Thimm A; Carpinteiro A; Oubari S; Papathanasiou M; Kessler L; Rischpler C; Malik RA; Herrmann K; Reinhardt HC; Rassaf T; Kleinschnitz C; Hagenacker T; Stettner M
J Neurol; 2023 Jul; 270(7):3483-3491. PubMed ID: 37014422
[TBL] [Abstract][Full Text] [Related]
20. The neuropathy in hereditary transthyretin amyloidosis: A narrative review.
Tozza S; Severi D; Spina E; Iovino A; Aruta F; Ruggiero L; Dubbioso R; Iodice R; Nolano M; Manganelli F
J Peripher Nerv Syst; 2021 Jun; 26(2):155-159. PubMed ID: 33960565
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
